Sanofi's Sarclisa 获得欧盟批准 多次间皮瘤治疗, 第一次抗CD38疗法。 Sanofi's Sarclisa gets EU approval for multiple myeloma treatment, a first for anti-CD38 therapy.

Sanofi的药物Sarclisa在欧盟获得批准, 用于治疗新诊断出无法进行干细胞移植的多细胞瘤患者。 Sanofi's drug Sarclisa has been approved in the EU for treating adults with newly diagnosed multiple myeloma who can't have a stem cell transplant. 该药物是经批准与标准治疗方案VRd一起使用的第一种抗CD38疗法。 The medication is the first anti-CD38 therapy approved for use with the standard treatment regimen VRd. 包括美国在内的50多个国家批准了Sarclisa方案,目的是根据第三阶段的研究结果,改善这些病人的无进展生存能力。 Approved in over 50 countries, including the US, Sarclisa aims to improve progression-free survival in these patients based on phase 3 study results.